Article info
PDFRecent advances in clinical practice
Novel therapeutic targets for cholestatic and fatty liver disease
- Correspondence to Professor Michael Trauner, Abteilung für Gastroenterologie & Hepatologie, Innere Medizin III, Medizinische Universitat Wien, Wien, Austria; michael.trauner{at}meduniwien.ac.at
Citation
Novel therapeutic targets for cholestatic and fatty liver disease
Publication history
- Received February 2, 2021
- Accepted August 6, 2021
- First published October 6, 2021.
Online issue publication
February 02, 2022
Article Versions
- Previous version (10 January 2022).
- Previous version (10 January 2022).
- Previous version (10 January 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.